Table 1 Clinicopathologic features of patients with lineage-switching leukemia.

From: Genetics and pathologic landscape of lineage switch of acute leukemia during therapy

Case #

Sex

Age at acute #1

Dx of acute #1

Tx of acute #1

Dz status of acute #1 at dx of acute #2

Dx of acute #2

Interval from acute #1 to #2

Tx of acute #2

Pt status at last F/U

Dz status of acute #1 at last F/U

Dz status of acute #2 at last F/U

OS from acute #1

OS from acute #2

1

M

0.1

B-ALL

Chemo

CR by FC

AML, Mono

7.8

Chemo

DOD#2

CR by FC

Persistent AML

9.1

1.3

2

M

0.1

B-ALL

Chemo, Blina

CR by FC

AML, Mono

3.9

Chemo

DOD#2

MRD+ by FC

Persistent AML

11.0

7.1

3

M

0.2

B-ALL

Chemo

12% by FC

AML, Mono

5.1

Chemo

DOD#1

Switch back

Residual AML

7.9

2.8

4

F

12.8

B-ALL

Chemo, CART

CR by FC

AML, M1

15.5

Chemo

Alive

CR by FC

Persistent AML

17.2

1.8

5

F

27.5

B-ALL

Chemo, SCT

CR by FC

AML, Mono

9.0

Chemo

DOD#2

CR by FC

MS

14.3

5.3

6

M

34.6

B-ALL

Chemo, R, Blina, Ino, SCT

CR by FC

AML, MS, Mono

7.4

Chemo

DOD#2

CR by FC

Persistent AML

10.0

2.6

7

M

40.2

B-ALL

Chemo, Blina

CR by FC

AML, M4

4.3

Chemo

DOD#2

CR by FC

Persistent AML

6.8

2.6

8

F

43.2

B-ALL

Chemo, R, Ino, Blina

CR by FC

AML, Mono

10.1

Chemo

DOD#2

CR by FC

Persistent AML

12.0

1.9

9

M

44.6

B-ALL

Chemo, Blina

CR by FC

AML, Mono

4.6

Chemo, SCT

DOD#2

CR by FC

Relapsed AML

10.6

6.1

10

F

46.2

B-ALL

Chemo, SCT, Blina

4% by FC

MS, Mono

12.4

Chemo

DOD#2

CR by FC

MS

13.4

1.0

11

F

61.8

B-ALL

Chemo, Blina, Ino

CR by FC

AML, M4

6.2

Chemo

DOD#1

Switch back

CR by FC

12.4

6.1

12

F

60.1

B-ALL

Chemo

CR by FC

AML, Mono

8.0

No

DOD#2

MRD+ by FC

Persistent AML

9.3

1.3

13

F

65.9

B-ALL

Chemo

CR by morphology

AML, Mono

0.9

Chemo, SCT

Alive

CR by FC

CR by Fc

23.9

23.0

14

M

1.1

B-ALL

Chemo

CR by FC

AML, Mono

14.7

Chemo, SCT

Alive

CR by FC

CR by FC

43.7

29.0

15

M

0.3

B-ALL

Chemo, CART

CR by FC

AML, Mono

8.5

Chemo, SCT

Alive

CR by FC

CR by FC

15.6

7.1

16

M

7.1

B-ALL

Chemo

CR by FC

AML, Mono

38.2

Chemo

DOD#2

CR by FC

Persistent AML

39.9

1.7

17

F

67.3

B-ALL

Chemo, R, Ino, Blina

0.4% by FC

AML, M0

6.2

Chemo

DOD#2

MRD+ by FC

Persistent AML

10.7

5.0

18

M

15

B-ALL

Chemo, Ino

CR by FC

AML, M4

4.8

Chemo

Alive

CR by FC

CR by FC

6.9

2.1

19

M

36.1

B-ALLa

Chemo, R

CR by FC

AML, M4

5.6

Chemo, SCT

DOD#2

CR by FC

Relapsed AML, MS

28.7

23.1

20

M

23.4

B-ALLb

Chemo, SCT

CR by FC

AML, Mono

7.7

Chemo

DOD#1

Switch back

Residual AML

9.3

1.7

21

M

69.6

B-ALLb

Chemo

1% by FC

AML, M6

12.2

No

DOD#2

MRD+ by FC

AML, not treated

12.4

0.2

22

M

21.2

B-AL Lc

Chemo, SCT

CR by FC

AML, M2 (MRC)

12.0

Chemo

Alive

CR by FC

Persistent AML

17.4

5.5

23

F

83.1

B-ALLc

Chemo, R, Blina

0.2% by FC

AML, M0

4.9

Chemo

DOD#2

MRD+ by FC

Persistent AML

5.9

1.0

24

M

83.2

B-ALLd

Chemo, Ofa

CR by FC

AML, M2

7.3

No

DOD#2

CR by FC

AML, not treated

8.0

0.7

25

M

69.1

B-ALLe

Chemo, Blina

CR by FC

AML, M6

6.0

NA

DOD#2

CR by FC

Persistent AML

7.2

1.1

26

M

52.5

B-LyBPf

Chemo

CR by FC

MyBP

6.2

Chemo

DOD#2

CR by FC

Persistent MyBP

7.7

1.5

27

M

12.8

T-ALL

Chemo

CR by FC

AML, M0

24.3

Chemo, SCT

Dead

NA

NA

117.9

93.7

28

M

13

T-ALL

Chemo

CR by FC

AML, M4

6.0

Chemo

DOD#2

CR by FC

Persistent AML

8.0

2.0

29

F

9.7

T-ALL

Chemo, SCT

CR by FC

AML, M0

14.6

NA

Alive #2

CR by FC

Persistent AML

15.3

0.7

30

F

0.6

AML, Mono

Chemo

10% by FC

B-ALL

9.8

Chemo, SCT

Dead from SCT

CR by FC

CR by FC

18.4

8.6

31

M

1.5

AML, Mono

Chemo

CR by FC

B-ALL

12.9

Chemo, SCT

Alive

CR by FC

CR by FC

179.4

166.6

32

M

73.6

AML, M2

Chemo

CR by FC

B-ALL

13.8

Chemo

Dead

NA

NA

18.3

4.5

33

M

68.1

AML, M0, (MRC)c

Chemo

CR by FC

B-ALL

25.8

Chemo

DOD#2

CR by FC

Persistent B-ALL

26.1

0.4

  1. ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, Bina Blinatumomab, CART Chimeric antigen receptor T-cell therapy, Chemo chemotherapy, CML chronic myeloid leukemia, CP chronic phase, CR complete remission, DOD die with disease, Dx diagnosis, Dz disease, FC flow cytometry, F/U follow-up, Ino Inotuzumab, LBL lymphoblastic lymphoma, LyBP lymphoid blast phase, MMR major molecular remission, Mono monoblastic or monocytic morphology, MRC myelodysplasia-related changes, MS myeloid sarcoma, MyBP myeloid blast phase, NA not available, Ofa Ofatumumab, OS overall survival, Pt patient, R Rituximab, SCT allogeneic stem cell transplant, TKI tyrosine kinase inhibitor, Tx treatment.
  2. aOccult myeloid/lymphoid neoplasm with JAK2 rearrangement.
  3. bOccult myelodysplastic syndrome.
  4. cHistory of myelodysplastic syndrome.
  5. dHistory of polycythemia vera.
  6. eHistory of primary myelofibrosis.
  7. fHistory of chronic myeloid leukemia.
Back to article page